Compare TAK & CCEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAK | CCEP |
|---|---|---|
| Founded | 1781 | 1986 |
| Country | Japan | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1B | 51.0B |
| IPO Year | 2007 | 2015 |
| Metric | TAK | CCEP |
|---|---|---|
| Price | $21.82 | $115.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $24.48 | ★ $113.29 |
| AVG Volume (30 Days) | ★ 3.1M | 1.5M |
| Earning Date | 10-29-2026 | 08-04-2026 |
| Dividend Yield | 1.12% | ★ 2.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.79 | $3.77 |
| Revenue Next Year | $2.44 | $4.29 |
| P/E Ratio | $41.25 | ★ $20.93 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.16 | $84.66 |
| 52 Week High | $21.86 | $120.41 |
| Indicator | TAK | CCEP |
|---|---|---|
| Relative Strength Index (RSI) | 69.50 | 53.69 |
| Support Level | $17.66 | $90.22 |
| Resistance Level | N/A | $119.09 |
| Average True Range (ATR) | 0.33 | 2.27 |
| MACD | -0.01 | -0.38 |
| Stochastic Oscillator | 82.22 | 46.70 |
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.